je.st
news
Home
› FDA Accepts For Review ELIQUIS (apixaban) Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And For The Reduction In The Risk Of Recurrent DVT And PE
FDA Accepts For Review ELIQUIS (apixaban) Supplemental New Drug Application For The Treatment Of Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE), And For The Reduction In The Risk Of Recurrent DVT And PE
2013-12-30 05:21:47| drugdiscoveryonline News Articles
Bristol-Myers Squibb Company and Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Supplemental New Drug Application (sNDA) for ELIQUIS (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE
Tags: the
of
and
review
Category:Biotechnology and Pharmaceuticals